Clinical study of sequential therapy for refractory heart failure with vasodilator

Effectiveness of vasodilator terazosin therapy in patients with refractory heart failure for four weeks and one year

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009291

Enrollment

Unknown

Registered

2016-09-28

Start date

2012-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angiocardiopathy

Interventions

1:Basal treatment + terazosin

2:Basal treatment

Eligibility

Sex/Gender

All

Age

48 Years to 92 Years

Inclusion criteria

Inclusion criteria: European Society of Cardiology definition of Refractory Heart Failure 1. Dyspnea and fatigue when at rest and/or during mild activity (New York Heart Association cardiac function class III or IV); 2. Pulmonary or other organ congestion, peripheral edema in the resting state, or inadequate cardiac output leading to peripheral hypoperfusion; 3. Inclusion of at least one objective evidence of severe heart failure: (1) Left ventricular ejection fraction 16 mmHg or right pulmonary artery (RPA) pressure >12 mmHg (floating catheter results) (4) Brain sodium peptide (BNP) and/or N-terminal-brain natriuretic peptide precursor (NT- proBNP) concentration increased out of heart reason; 4. Serious heart function damage to one of the following presentations: (1) Disability; (2) Six minute walking distance test <300 m; (3) Peak O2 <12-14 mL?kg -1?min-1; 5. Hospitalized for heart failure at least once in the past six months; 6. Patients with symptoms that did not improve after effective diuretic and strict treatment according to guidelines or patients with CRT indication.

Exclusion criteria

Exclusion criteria: 1.Patients who do not cooperate with the use of the drug therapy 2.Patients who do not cooperate with the relevant examination 3.Patients who do not meet the criteria for refractory heart failure

Design outcomes

Primary

Measure	Time frame
Heart function;Ejection fraction;brain natriuretic peptide;6 minute walk distance;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;	—

Countries

China

Contacts

Public ContactJinfeng Yang

Jixian People's Hospital of Tianjin

13820970878@126.com+86 13820970878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026